409 related articles for article (PubMed ID: 26698587)
1. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
Finkelstein PE
AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
[No Abstract] [Full Text] [Related]
2. The strange allure of state "right-to-try" laws.
Zettler PJ; Greely HT
JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589
[No Abstract] [Full Text] [Related]
3. Food and Drug Administration responds to pressure for expanded drug access.
Brower V
J Natl Cancer Inst; 2014 Jun; 106(6):dju171. PubMed ID: 24907387
[No Abstract] [Full Text] [Related]
4. Expanded access rules pose quandary for drug developers.
Mack GS
Nat Biotechnol; 2009 Oct; 27(10):871-2. PubMed ID: 19816423
[No Abstract] [Full Text] [Related]
5. The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward.
Bateman-House A; Robertson CT
JAMA Intern Med; 2018 Mar; 178(3):321-322. PubMed ID: 29356821
[No Abstract] [Full Text] [Related]
6. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
Puthumana J; Miller JE; Kim J; Ross JS
JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
[TBL] [Abstract][Full Text] [Related]
7. Implementation of 21st Century Cures Act Expanded Access Policies Requirements.
Kang S; Chang S; Ross JS; Miller JE
Clin Pharmacol Ther; 2021 Dec; 110(6):1579-1584. PubMed ID: 34431083
[TBL] [Abstract][Full Text] [Related]
8. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
[No Abstract] [Full Text] [Related]
9. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Ochs A
Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
[No Abstract] [Full Text] [Related]
10. Fairer way to distribute last-ditch drugs gets real-world trial.
Reardon S
Nature; 2016 Jun; 534(7606):160-1. PubMed ID: 27279187
[No Abstract] [Full Text] [Related]
11. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE
Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691
[TBL] [Abstract][Full Text] [Related]
12. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
13. Questions of Safety and Fairness Raised as Right-to-Try Movement Gains Steam.
Jacob JA
JAMA; 2015 Aug; 314(8):758-60. PubMed ID: 26244653
[No Abstract] [Full Text] [Related]
14. Should patients in need be given access to experimental drugs?
Caplan AL; Bateman-House A
Expert Opin Pharmacother; 2015 Jun; 16(9):1275-9. PubMed ID: 26001178
[TBL] [Abstract][Full Text] [Related]
15. Attorneys aim to reform "compassionate use": groups say the regulatory system lags behind scientific advances.
Printz C
Cancer; 2015 Jan; 121(2):163-4. PubMed ID: 25581115
[No Abstract] [Full Text] [Related]
16. Looking for a miracle.
Marchant J
New Sci; 2000 Jun; 166(2244):16-7. PubMed ID: 11902203
[No Abstract] [Full Text] [Related]
17. Drugs with breakthrough status charm investors.
Senior M
Nat Biotechnol; 2013 Nov; 31(11):945-7. PubMed ID: 24213748
[No Abstract] [Full Text] [Related]
18. Maine law requires drug companies to provide clinical trial data.
Appell D
J Natl Cancer Inst; 2005 Sep; 97(17):1246. PubMed ID: 16145043
[No Abstract] [Full Text] [Related]
19. A critical tipping point.
Zuckerman MB
US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
[No Abstract] [Full Text] [Related]
20. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
[Next] [New Search]